Immupharma PLC Corporate Update (1178Y)
May 07 2019 - 2:01AM
UK Regulatory
TIDMIMM
RNS Number : 1178Y
Immupharma PLC
07 May 2019
7 May 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
CORPORATE UPDATE
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and
development company provides an update on ongoing activities.
Lupuzor(TM)
Lupuzor(TM) is the Company's late stage asset for Lupus, a
potential life threatening auto-immune disease. Following the
conclusion of the pivotal Phase III trial in 2018, ImmuPharma
continues to look at opportunities which the Board believes over
the longer term have the potential of bringing Lupuzor(TM) to
market. As part of this strategy, the Company confirms that it
continues to engage with potential corporate partners as well as
consulting with regulatory advisors on potential pathways to
market. Whilst these activities continue the commencement of the
Managed Access Program for Lupuzor(TM) will be postponed until the
Company has further clarification on these activities.
Lupuzor(TM) Extension Study
The Lupuzor(TM) open label extension study, from the original
Phase III trial, with a total of 62 eligible patients recruited
throughout the US and Europe, remains on track to report results in
Q2 2019.
Merger of Elro Pharma and Ureka
ImmuPharma's subsidiaries Elro Pharma Sarl and Ureka Sarl, both
based in France, are focussing on unique technologies: the Nucant
cancer programme (Elro) and the peptide platform (Ureka).
As previously announced, the Company has been exploring its
options to licence, divest or 'spin-off' the technologies of both
of these subsidiaries to unlock their future potential and enhance
value to shareholders.
Following an internal review, the Company's intention is to
merge these two subsidiaries, in order to create a stronger
combined company with a platform technology together with a drug
candidate in clinical development, with a view to securing external
investment either from private equity or through a public listing
on a European stock exchange. This in turn would allow ImmuPharma
PLC to focus on Lupuzor(TM) and the overall P140 platform for
different autoimmune indications
Further details will be announced in due course.
Incanthera Limited
Further to the announcement of 1 April 2019, all discussions
with Incanthera on the Nucant cancer programme and broader
collaboration discussions have now terminated.
Final Results
ImmuPharma will provide a further update on its operations and
strategy in its Final results for the year ended 31 December 2018,
which are expected to be announced by the end of this month.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC (www.immupharma.com) + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
BACKGROUND NOTES HERE INCLUDING P140.....................
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDAFMMTMBTMTRL
(END) Dow Jones Newswires
May 07, 2019 02:01 ET (06:01 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024